• Matinas BioPharma received an NYSE American notice citing non-compliance with continued listing standards tied to minimum stockholders’ equity.
• Stockholders’ equity stood at $1.8 million as of June 30, 2026, below the $2 million threshold under Section 1003(a)(i).
• NYSE American accepted a remediation plan, granting a compliance window through Oct. 2, 2027.
• Failure to regain compliance or meet plan milestones by the deadline could trigger delisting proceedings, subject to appeal rights.
• Shares remain listed during the plan period, with a .BC indicator attached to the ticker until compliance is restored.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Matinas BioPharma Holdings Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202609041700PRIMZONEFULLFEED9821071) on September 04, 2026, and is solely responsible for the information contained therein.